India · Delayed Price · Currency is INR Emcure Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw 16.6% revenue growth, 41% adjusted PAT growth, and margin expansion, driven by strong international and resilient domestic performance. FY 2027 guidance is for low-to-mid-teen revenue growth and further margin gains, with Zuventus integration stabilizing.
-
Q3 FY26 saw 20.4% revenue growth and 48% PAT increase, driven by strong domestic and international performance, strategic in-licensing, and new launches like semaglutide. EBITDA margin improved to 19.5%, with a positive outlook for sustained growth and margin expansion.
-
Q2 FY2026 saw 13% revenue growth and record profits, driven by strong domestic and international performance. Strategic moves included a Novo Nordisk partnership for Semaglutide and full Zuventus acquisition, with margin and debt targets updated following recent M&A.
-
Q1 FY2026 delivered strong growth with revenue up 15.7% and profit after tax up 41% year-over-year. Domestic and international segments both outperformed, with new product launches and partnerships driving momentum. EBITDA margin improved to 19.2%.
Fiscal Year 2025
-
FY 2025 saw 19% revenue growth and 34% PAT increase, driven by strong domestic and international performance, portfolio expansion, and successful integration of acquisitions. FY 2026 guidance targets 13-14% revenue growth, 150 bps margin improvement, and further debt reduction.
-
Q3 FY25 saw 18% revenue growth and 36% adjusted PAT growth, led by strong international and domestic performance. Margins are expected to improve over the next few years, with new launches in derma and ophthalmology, and a focus on vertical integration for semaglutide.